

## Serplulimab: Adis Evaluation

### Key Points

- An anti-PD-1 monoclonal antibody is being developed by Shanghai Henlius Biotech, Inc. for the treatment of solid tumours
- Received its first approval on 25 Mar 2022 in China
- Approved for use in the treatment of adult patients with advanced unresectable or metastatic MSI-H solid tumours that have failed to respond to previous standard treatments

### Summary

Serplulimab (汉斯状®) is an intravenously administered anti-PD-1 antibody being developed by Shanghai Henlius Biotech, Inc. for the treatment of solid tumours.

Anti-PD-1 immunotherapies, such as serplulimab, can stimulate immune responses by relieving PD-1-related immunosuppression.

Serplulimab received its first approval on 25 Mar 2022 in China for the treatment of adult patients with advanced unresectable or metastatic microsatellite instability-high (MSI-H) solid tumours that have failed to respond to previous standard treatments.

This summary represents the opinions of the author. For a full list of declarations, including funding and author disclosure statements, please see the full text online. © Springer Nature Switzerland AG 2022.